Synthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer

Yajuan Li, Zheng Han, Sarah Roelle, Aidan DeSanto, Rob Sabatelle, Rebecca Schur, Zheng Rong Lu

Research output: Contribution to journalArticle

Abstract

Contrast enhanced MRI is commonly used in imaging and treatment planning of prostate cancer. However, no tumor targeting contrast agent is commercially available for accurate detection and characterization of prostate cancer with MRI. Extradomain B fibronectin (EDB-FN), an oncoprotein present in aggressive tumors, is a promising molecular target for detection and stratification of high-risk prostate cancer. In this work, we have identified four small peptides (GVK, IGK, SGV, and ZD2) specific to EDB-FN for tumor targeting. In silico simulations of the binding patterns and affinities of peptides to the EDB protein fragment revealed different binding site to different peptide in the ligand-receptor interactions. Tumor specificity and organ distribution of the peptides were assessed using fluorescence imaging in male mice bearing PC-3 human prostate cancer xenografts. Targeted contrast agents were synthesized by conjugating tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the peptides in the solid phase, followed by complexation with GdCl3. The contrast agents were characterized by MALDI-TOF mass spectrometry and relaxivity measurements. All four peptide Gd-DOTA conjugates resulted in robust tumor contrast enhancement in MR imaging of the PC3 mouse prostate cancer model. The peptide Gd-DOTA conjugates specific to EDB-FN are promising targeted small molecular macrocyclic contrast agents for MR molecular imaging of prostate cancer.

Original languageEnglish (US)
Pages (from-to)3906-3915
Number of pages10
JournalMolecular Pharmaceutics
Volume14
Issue number11
DOIs
StatePublished - Nov 6 2017
Externally publishedYes

Fingerprint

Molecular Imaging
Fibronectins
Prostatic Neoplasms
Magnetic Resonance Imaging
Peptides
Contrast Media
Neoplasms
Organ Specificity
Optical Imaging
Oncogene Proteins
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate
Heterografts
Computer Simulation
Mass Spectrometry
Binding Sites
Ligands

Keywords

  • EDB fibronectin
  • MRI
  • peptide
  • prostate cancer
  • targeted contrast agent

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Synthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer. / Li, Yajuan; Han, Zheng; Roelle, Sarah; DeSanto, Aidan; Sabatelle, Rob; Schur, Rebecca; Lu, Zheng Rong.

In: Molecular Pharmaceutics, Vol. 14, No. 11, 06.11.2017, p. 3906-3915.

Research output: Contribution to journalArticle

Li, Yajuan ; Han, Zheng ; Roelle, Sarah ; DeSanto, Aidan ; Sabatelle, Rob ; Schur, Rebecca ; Lu, Zheng Rong. / Synthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer. In: Molecular Pharmaceutics. 2017 ; Vol. 14, No. 11. pp. 3906-3915.
@article{cb766faadd3742a398308e5e0285b60c,
title = "Synthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer",
abstract = "Contrast enhanced MRI is commonly used in imaging and treatment planning of prostate cancer. However, no tumor targeting contrast agent is commercially available for accurate detection and characterization of prostate cancer with MRI. Extradomain B fibronectin (EDB-FN), an oncoprotein present in aggressive tumors, is a promising molecular target for detection and stratification of high-risk prostate cancer. In this work, we have identified four small peptides (GVK, IGK, SGV, and ZD2) specific to EDB-FN for tumor targeting. In silico simulations of the binding patterns and affinities of peptides to the EDB protein fragment revealed different binding site to different peptide in the ligand-receptor interactions. Tumor specificity and organ distribution of the peptides were assessed using fluorescence imaging in male mice bearing PC-3 human prostate cancer xenografts. Targeted contrast agents were synthesized by conjugating tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the peptides in the solid phase, followed by complexation with GdCl3. The contrast agents were characterized by MALDI-TOF mass spectrometry and relaxivity measurements. All four peptide Gd-DOTA conjugates resulted in robust tumor contrast enhancement in MR imaging of the PC3 mouse prostate cancer model. The peptide Gd-DOTA conjugates specific to EDB-FN are promising targeted small molecular macrocyclic contrast agents for MR molecular imaging of prostate cancer.",
keywords = "EDB fibronectin, MRI, peptide, prostate cancer, targeted contrast agent",
author = "Yajuan Li and Zheng Han and Sarah Roelle and Aidan DeSanto and Rob Sabatelle and Rebecca Schur and Lu, {Zheng Rong}",
year = "2017",
month = "11",
day = "6",
doi = "10.1021/acs.molpharmaceut.7b00619",
language = "English (US)",
volume = "14",
pages = "3906--3915",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "11",

}

TY - JOUR

T1 - Synthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer

AU - Li, Yajuan

AU - Han, Zheng

AU - Roelle, Sarah

AU - DeSanto, Aidan

AU - Sabatelle, Rob

AU - Schur, Rebecca

AU - Lu, Zheng Rong

PY - 2017/11/6

Y1 - 2017/11/6

N2 - Contrast enhanced MRI is commonly used in imaging and treatment planning of prostate cancer. However, no tumor targeting contrast agent is commercially available for accurate detection and characterization of prostate cancer with MRI. Extradomain B fibronectin (EDB-FN), an oncoprotein present in aggressive tumors, is a promising molecular target for detection and stratification of high-risk prostate cancer. In this work, we have identified four small peptides (GVK, IGK, SGV, and ZD2) specific to EDB-FN for tumor targeting. In silico simulations of the binding patterns and affinities of peptides to the EDB protein fragment revealed different binding site to different peptide in the ligand-receptor interactions. Tumor specificity and organ distribution of the peptides were assessed using fluorescence imaging in male mice bearing PC-3 human prostate cancer xenografts. Targeted contrast agents were synthesized by conjugating tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the peptides in the solid phase, followed by complexation with GdCl3. The contrast agents were characterized by MALDI-TOF mass spectrometry and relaxivity measurements. All four peptide Gd-DOTA conjugates resulted in robust tumor contrast enhancement in MR imaging of the PC3 mouse prostate cancer model. The peptide Gd-DOTA conjugates specific to EDB-FN are promising targeted small molecular macrocyclic contrast agents for MR molecular imaging of prostate cancer.

AB - Contrast enhanced MRI is commonly used in imaging and treatment planning of prostate cancer. However, no tumor targeting contrast agent is commercially available for accurate detection and characterization of prostate cancer with MRI. Extradomain B fibronectin (EDB-FN), an oncoprotein present in aggressive tumors, is a promising molecular target for detection and stratification of high-risk prostate cancer. In this work, we have identified four small peptides (GVK, IGK, SGV, and ZD2) specific to EDB-FN for tumor targeting. In silico simulations of the binding patterns and affinities of peptides to the EDB protein fragment revealed different binding site to different peptide in the ligand-receptor interactions. Tumor specificity and organ distribution of the peptides were assessed using fluorescence imaging in male mice bearing PC-3 human prostate cancer xenografts. Targeted contrast agents were synthesized by conjugating tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the peptides in the solid phase, followed by complexation with GdCl3. The contrast agents were characterized by MALDI-TOF mass spectrometry and relaxivity measurements. All four peptide Gd-DOTA conjugates resulted in robust tumor contrast enhancement in MR imaging of the PC3 mouse prostate cancer model. The peptide Gd-DOTA conjugates specific to EDB-FN are promising targeted small molecular macrocyclic contrast agents for MR molecular imaging of prostate cancer.

KW - EDB fibronectin

KW - MRI

KW - peptide

KW - prostate cancer

KW - targeted contrast agent

UR - http://www.scopus.com/inward/record.url?scp=85033365945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033365945&partnerID=8YFLogxK

U2 - 10.1021/acs.molpharmaceut.7b00619

DO - 10.1021/acs.molpharmaceut.7b00619

M3 - Article

C2 - 28976766

AN - SCOPUS:85033365945

VL - 14

SP - 3906

EP - 3915

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 11

ER -